TScan Therapeutics, Inc.
TCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $21 | $14 | $10 |
| % Growth | -86.6% | 55.5% | 33.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3 | $21 | $14 | $10 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $107 | $88 | $60 | $45 |
| G&A Expenses | $30 | $25 | $20 | $14 |
| SG&A Expenses | $30 | $25 | $20 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Expenses | $138 | $115 | $80 | $59 |
| Operating Income | -$135 | -$93 | -$67 | -$49 |
| % Margin | -4,787.7% | -444% | -492.3% | -479.6% |
| Other Income/Exp. Net | $7 | $4 | $0 | $0 |
| Pre-Tax Income | -$127 | -$89 | -$66 | -$49 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$127 | -$89 | -$66 | -$49 |
| % Margin | -4,527.7% | -423.9% | -489.3% | -479.5% |
| EPS | -1.14 | -1.36 | -2.74 | -2.03 |
| % Growth | 16.2% | 50.4% | -35% | – |
| EPS Diluted | -1.14 | -1.36 | -2.74 | -2.03 |
| Weighted Avg Shares Out | 112 | 66 | 24 | 24 |
| Weighted Avg Shares Out Dil | 112 | 66 | 24 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $8 | $2 | $0 |
| Interest Expense | $4 | $4 | $1 | $0 |
| Depreciation & Amortization | $4 | $5 | $5 | $3 |
| EBITDA | -$120 | -$80 | -$60 | -$45 |
| % Margin | -4,252.1% | -380.5% | -442.6% | -446.7% |